Figure 2.

RD2RD2 administration resulted in a non-significant shift of disease onset of SOD1*G93A mice. Assessment of disease was performed three times a week from the start of the experiment. Disease onset is defined as first defects detectable in hind limb splay and an increasing tremor. RD2RD2-treated SOD1*G93A mice had a delayed onset of disease symptoms vs. placebo group. One treated mouse did not develop a tremor in hind limbs until the end of the experiment. Statistical calculations were conducted by Kaplan–Meier survival analysis and the log-rank analysis, RD2RD2 n = 12 and placebo n = 10.